for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Epizyme Inc

EPZM.OQ

Latest Trade

11.06USD

Change

-0.09(-0.81%)

Volume

628,753

Today's Range

10.85

 - 

11.31

52 Week Range

5.14

 - 

16.59

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
11.15
Open
11.11
Volume
628,753
3M AVG Volume
16.62
Today's High
11.31
Today's Low
10.85
52 Week High
16.59
52 Week Low
5.14
Shares Out (MIL)
91.04
Market Cap (MIL)
1,015.06
Forward P/E
-5.16
Dividend (Yield %)
--

Next Event

Q3 2019 Epizyme Inc Earnings Release

Latest Developments

More

Epizyme Inc - Paolo Tombesi Appointed As Chief Financial Officer

Epizyme Announces FDA Filing Acceptance Of New Drug Application And Priority Review For Tazemetostat

Epizyme Reports Updated Data From Phase 2 Trial Of Tazemetostat

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Epizyme Inc

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.

Industry

Biotechnology & Drugs

Contact Info

400 Technology Sq Ste 4

+1.617.2295872

http://www.epizyme.com/

Executive Leadership

David M. Mott

Independent Chairman of the Board

Robert B. Bazemore

President, Chief Executive Officer, Director

Paolo Tombesi

Chief Financial Officer

Joseph Beaulieu

Corporate Controller and Treasurer

Shefali Agarwal

Chief Medical Officer

Key Stats

1.50 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.930

2017

-2.180

2018

-1.720

2019(E)

-2.162
Price To Earnings (TTM)
--
Price To Sales (TTM)
43.21
Price To Book (MRQ)
3.52
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-50.49
Return on Equity (TTM)
-45.27

Latest News

CORRECTED-BRIEF-Epizyme Reports Q3 Loss of $0.54 Per Share

* EPIZYME REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND TAZEMETOSTAT PROGRESS

BRIEF-Epizyme Reports Q1 Loss Per Share Of $0.49

* EPIZYME REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

BRIEF-Epizyme Provides Update Regarding Tazemetostat Clinical Program

* EPIZYME PROVIDES UPDATE REGARDING TAZEMETOSTAT CLINICAL PROGRAM

BRIEF-Epizyme Inc Files For Potential Mixed Shelf, Size Not Disclosed

* EPIZYME INC FILES FOR POTENTIAL MIXED SHELF; SIZE NOT DISCLOSED - SEC FILING Source text: (https://bit.ly/2q8HM38) Further company coverage:

BRIEF-Epizyme Q4 Loss Per Share $0.52

* EPIZYME REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING RESULTS AND 2018 MILESTONES

BRIEF-Epizyme announces pricing of public offering of common stock

* Epizyme announces pricing of public offering of common stock

BRIEF-Epizyme reports Q2 loss of $0.48/shr

* Epizyme reports second quarter 2017 financial results and clinical and business progress

BRIEF-US Oncology Research and Epizyme establish collaboration to identify non-hodgkin lymphoma patients with EZH2 mutations

* US Oncology Research and Epizyme establish collaboration to identify non-hodgkin lymphoma patients with EZH2 mutations

BRIEF-Epizyme announces Tazemetostat to be evaluated in NCI-COG pediatric MATCH trial

* Epizyme announces Tazemetostat to be evaluated in NCI’s recently initiated NCI-COG pediatric MATCH trial Source text for Eikon: Further company coverage:

BRIEF-Epizyme expands clinical collaboration with Genentech

* Epizyme expands clinical collaboration to study tazemetostat and tecentriq® combination in nsclc

BRIEF-Epizyme announces tazemetostat granted orphan drug designation

* Epizyme announces tazemetostat granted orphan drug designation for the treatment of soft tissue sarcoma Source text for Eikon: Further company coverage:

BRIEF-Epizyme reports positive interim data from Phase 2 trial for tazemetostat

* Epizyme reports positive interim data from Phase 2 trial for tazemetostat in relapsed or refractory follicular lymphoma and dlbcl patients

BRIEF-Epizyme quarterly loss per share $0.56

* Quarterly loss per share $0.56 Source text: (http://bit.ly/2qgKGVs) Further company coverage:

BRIEF-Epizyme Earns $10 million milestone payment from Glaxosmithkline

* Epizyme earns $10 million milestone payment from glaxosmithkline for initiation of GLP Toxicology studies with novel methyltransferase inhibitor

BRIEF-Epizyme announces tazemetostat fast track designation for follicular lymphoma and plenary session on Phase 2 NHL data at ICML

* Epizyme announces tazemetostat fast track designation for follicular lymphoma and plenary session on Phase 2 NHL data at ICML

BRIEF-Epizyme qtrly loss per share $0.60

* Epizyme reports 2016 financial results and provides 2017 pipeline goals

BRIEF-Epizyme elects Kevin Conroy to its board of directors

* Epizyme elects Kevin Conroy to its board of directors Source text for Eikon: Further company coverage:

BRIEF-Epizyme receives positive written response from FDA allowing enrollment of patients with follicular lymphoma in U.S.

* Epizyme Inc - received a positive written response from FDA allowing enrollment of patients with follicular lymphoma in U.S.

BRIEF-Epizyme announces fast track designation for Tazemetostat in DLBCL

* Epizyme announces fast track designation for tazemetostat in DLBCL and provides solid tumor program update

BRIEF-Epizyme Q3 loss per share $0.42

* Says plans to report efficacy, safety and biomarker data from both phase 2 studies on tazemetostat in first half of 2017

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up